Bioluminescent murine models of bacterial sepsis and scald wound infections for antimicrobial efficacy testing.
There are very few articles in the literature describing continuous models of bacterial infections that mimic disease pathogenesis in humans and animals without using separate cohorts of animals at each stage of disease. In this work, we developed bioluminescent mouse models of partial-thickness sca...
Main Authors: | , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2018-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC6047774?pdf=render |
id |
doaj-4632a4228f75497d92cafa7122a9bfbe |
---|---|
record_format |
Article |
spelling |
doaj-4632a4228f75497d92cafa7122a9bfbe2020-11-25T01:46:00ZengPublic Library of Science (PLoS)PLoS ONE1932-62032018-01-01137e020019510.1371/journal.pone.0200195Bioluminescent murine models of bacterial sepsis and scald wound infections for antimicrobial efficacy testing.Abiodun D OgunniyiZlatko KopeckiElizabeth E HickeyManouchehr KhazandiEmma PeelKatherine BelovAlexandra BoileauSanjay GargHenrietta VenterWei Yee ChanPeter B HillStephen W PageAllison J CowinDarren J TrottThere are very few articles in the literature describing continuous models of bacterial infections that mimic disease pathogenesis in humans and animals without using separate cohorts of animals at each stage of disease. In this work, we developed bioluminescent mouse models of partial-thickness scald wound infection and sepsis that mimic disease pathogenesis in humans and animals using a recombinant luciferase-expressing Staphylococcus aureus strain (Xen29). Two days post-scald wound infection, mice were treated twice daily with a 2% topical mupirocin ointment for 7 days. For sepsis experiments, mice were treated intraperitoneally with 6 mg/kg daptomycin 2 h and 6 h post-infection and time to moribund monitored for 72 h. Consistent bacterial burden data were obtained from individual mice by regular photon intensity quantification on a Xenogen IVIS Lumina XRMS Series III biophotonic imaging system, with concomitant significant reduction in photon intensities in drug-treated mice. Post-mortem histopathological examination of wounds and bacterial counts in blood correlated closely with disease severity and total flux obtained from Xen29. The bioluminescent murine models provide a refinement to existing techniques of multiple bacterial enumeration during disease pathogenesis and promote animal usage reduction. The models also provide an efficient and information-rich platform for preclinical efficacy evaluation of new drug classes for treating acute and chronic human and animal bacterial infections.http://europepmc.org/articles/PMC6047774?pdf=render |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Abiodun D Ogunniyi Zlatko Kopecki Elizabeth E Hickey Manouchehr Khazandi Emma Peel Katherine Belov Alexandra Boileau Sanjay Garg Henrietta Venter Wei Yee Chan Peter B Hill Stephen W Page Allison J Cowin Darren J Trott |
spellingShingle |
Abiodun D Ogunniyi Zlatko Kopecki Elizabeth E Hickey Manouchehr Khazandi Emma Peel Katherine Belov Alexandra Boileau Sanjay Garg Henrietta Venter Wei Yee Chan Peter B Hill Stephen W Page Allison J Cowin Darren J Trott Bioluminescent murine models of bacterial sepsis and scald wound infections for antimicrobial efficacy testing. PLoS ONE |
author_facet |
Abiodun D Ogunniyi Zlatko Kopecki Elizabeth E Hickey Manouchehr Khazandi Emma Peel Katherine Belov Alexandra Boileau Sanjay Garg Henrietta Venter Wei Yee Chan Peter B Hill Stephen W Page Allison J Cowin Darren J Trott |
author_sort |
Abiodun D Ogunniyi |
title |
Bioluminescent murine models of bacterial sepsis and scald wound infections for antimicrobial efficacy testing. |
title_short |
Bioluminescent murine models of bacterial sepsis and scald wound infections for antimicrobial efficacy testing. |
title_full |
Bioluminescent murine models of bacterial sepsis and scald wound infections for antimicrobial efficacy testing. |
title_fullStr |
Bioluminescent murine models of bacterial sepsis and scald wound infections for antimicrobial efficacy testing. |
title_full_unstemmed |
Bioluminescent murine models of bacterial sepsis and scald wound infections for antimicrobial efficacy testing. |
title_sort |
bioluminescent murine models of bacterial sepsis and scald wound infections for antimicrobial efficacy testing. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2018-01-01 |
description |
There are very few articles in the literature describing continuous models of bacterial infections that mimic disease pathogenesis in humans and animals without using separate cohorts of animals at each stage of disease. In this work, we developed bioluminescent mouse models of partial-thickness scald wound infection and sepsis that mimic disease pathogenesis in humans and animals using a recombinant luciferase-expressing Staphylococcus aureus strain (Xen29). Two days post-scald wound infection, mice were treated twice daily with a 2% topical mupirocin ointment for 7 days. For sepsis experiments, mice were treated intraperitoneally with 6 mg/kg daptomycin 2 h and 6 h post-infection and time to moribund monitored for 72 h. Consistent bacterial burden data were obtained from individual mice by regular photon intensity quantification on a Xenogen IVIS Lumina XRMS Series III biophotonic imaging system, with concomitant significant reduction in photon intensities in drug-treated mice. Post-mortem histopathological examination of wounds and bacterial counts in blood correlated closely with disease severity and total flux obtained from Xen29. The bioluminescent murine models provide a refinement to existing techniques of multiple bacterial enumeration during disease pathogenesis and promote animal usage reduction. The models also provide an efficient and information-rich platform for preclinical efficacy evaluation of new drug classes for treating acute and chronic human and animal bacterial infections. |
url |
http://europepmc.org/articles/PMC6047774?pdf=render |
work_keys_str_mv |
AT abiodundogunniyi bioluminescentmurinemodelsofbacterialsepsisandscaldwoundinfectionsforantimicrobialefficacytesting AT zlatkokopecki bioluminescentmurinemodelsofbacterialsepsisandscaldwoundinfectionsforantimicrobialefficacytesting AT elizabethehickey bioluminescentmurinemodelsofbacterialsepsisandscaldwoundinfectionsforantimicrobialefficacytesting AT manouchehrkhazandi bioluminescentmurinemodelsofbacterialsepsisandscaldwoundinfectionsforantimicrobialefficacytesting AT emmapeel bioluminescentmurinemodelsofbacterialsepsisandscaldwoundinfectionsforantimicrobialefficacytesting AT katherinebelov bioluminescentmurinemodelsofbacterialsepsisandscaldwoundinfectionsforantimicrobialefficacytesting AT alexandraboileau bioluminescentmurinemodelsofbacterialsepsisandscaldwoundinfectionsforantimicrobialefficacytesting AT sanjaygarg bioluminescentmurinemodelsofbacterialsepsisandscaldwoundinfectionsforantimicrobialefficacytesting AT henriettaventer bioluminescentmurinemodelsofbacterialsepsisandscaldwoundinfectionsforantimicrobialefficacytesting AT weiyeechan bioluminescentmurinemodelsofbacterialsepsisandscaldwoundinfectionsforantimicrobialefficacytesting AT peterbhill bioluminescentmurinemodelsofbacterialsepsisandscaldwoundinfectionsforantimicrobialefficacytesting AT stephenwpage bioluminescentmurinemodelsofbacterialsepsisandscaldwoundinfectionsforantimicrobialefficacytesting AT allisonjcowin bioluminescentmurinemodelsofbacterialsepsisandscaldwoundinfectionsforantimicrobialefficacytesting AT darrenjtrott bioluminescentmurinemodelsofbacterialsepsisandscaldwoundinfectionsforantimicrobialefficacytesting |
_version_ |
1725021442374893568 |